Randomised, placebo controlled, single-center, double-blind clinical trial to investigate efficacy and safety of aprepitant combined with Kevatril and dexamethasone versus placebo combined with Kevatril and dexamethasone in prevention of acute and delayed high-dose chemotherapy-induced nausea and vomiting in subjects with multiple myeloma receiving an autologous peripheral blood stemcell transplantation.

Trial Profile

Randomised, placebo controlled, single-center, double-blind clinical trial to investigate efficacy and safety of aprepitant combined with Kevatril and dexamethasone versus placebo combined with Kevatril and dexamethasone in prevention of acute and delayed high-dose chemotherapy-induced nausea and vomiting in subjects with multiple myeloma receiving an autologous peripheral blood stemcell transplantation.

Completed
Phase of Trial: Phase III

Latest Information Update: 27 Feb 2017

At a glance

  • Drugs Aprepitant (Primary) ; Dexamethasone; Granisetron
  • Indications Chemotherapy-induced nausea and vomiting
  • Focus Therapeutic Use
  • Acronyms EmNa
  • Most Recent Events

    • 12 Jul 2011 New source identified and integrated (European Clinical Trials Database; EudraCT2004-004956-38).
    • 13 Jan 2010 Planned end date changed from 1 Dec 2009 to 1 Dec 2010 as reported by ClinicalTrials.gov.
    • 01 Jan 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top